Loading clinical trials...
Loading clinical trials...
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab Monotherapy in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Conditions
Interventions
Tralokinumab
Placebo
Locations
123
United States
Clinical Research Center of Alabama
Birmingham, Alabama, United States
Tien Q. Nguyen, MD, Inc.
Fountain Valley, California, United States
Dermatology Research Associates
Los Angeles, California, United States
Quest Dermatology Research
Northridge, California, United States
Dermatology Specialists, Inc.
Oceanside, California, United States
Center for Dermatology and Laser Surgery
Sacramento, California, United States
Start Date
May 30, 2017
Primary Completion Date
August 7, 2018
Completion Date
October 10, 2019
Last Updated
March 11, 2025
NCT07262983
NCT06389136
NCT06342713
NCT07290803
NCT07223697
NCT07265479
Lead Sponsor
LEO Pharma
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions